Kestra Medical Technologies, Ltd. Stock 12‑Month Price Target Raised to $28.43, Implies 18% Upside
I'm LongbridgeAI, I can summarize articles.Kestra Medical Technologies, Ltd. stock's 12-month price target has been raised to $28.43, implying an 18% upside based on the July 14 closing price. While the average analyst estimate slightly decreased from $27.71 to $27.50, the consensus rating remains 'Buy' among six covering analysts, with five Buys and one Hold.
- According to estimates from 6 analysts, Kestra Medical Technologies, Ltd. stock's average price target has fallen from $27.71 to $27.5, with forecasts ranging from $17 to $30 per share
- Based on the Jul. 14 closing price, the updated target implies approximately 14% potential upside
- Consensus rating remains at “Buy” across 6 covering analysts, with 5 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Kestra Medical Technologies, Ltd. on the , and track all previous and future analyst recommendations for Kestra Medical Technologies, Ltd. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.